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enteroendocrine cells as these cells co-
store and co-release physiological mix-
tures of gut hormones, for example
GLP-1 together with PYY and GLP-2 in
the lower gut and ghrelin together with
motilin in the upper gut. Moreover, phar-
macokinetically you may only have to ob-
tain efficient receptor exposure in the gut
epithelium—with all the benefits this
would have in respect to limited side
effects, etc. On the other hand, you may
have to ensure that the drug is released
and is active only in a particular segment
of the gut as the same chemosensor may
be used on different enteroendocrine cells
and may serve different purposes in dif-
ferent parts of the GI tract. All of this will
become much clearer when we get a bet-
ter picture of this interesting control sys-
tem through technologies as described by
Reimann and coworkers (Reimann et al.,
2008) and Samuel and coworkers (Sam-
uel et al., 2008). Nevertheless, the first
compounds that function, at least partly,
through the release of gut hormones are
already in clinical trials, i.e., GPR119
agonists. Although the focus for these
compounds initially was on their effects
on pancreatic insulin secretion, attention
has recently included their effects on
GLP-1 release from the gut (Chu et al.,
2008). It is, however, highly likely that
GPR119 agonists will also release at least
PYY and GLP-2, because these pep-
tides—as mentioned above—are co-
stored and co-released, but possibly
also other gut hormones.
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All vertebrate animals have developed a sophisticated regulatory system to cope with frequent and unpre-
dictable episodes of fasting. A recent letter to Nature suggests that a switch from early gluconeogenic
gene activation via CRTC2 (also known as TORC2) to late action of FOXO1 is critical to this process.Maintenance of glucose homeostasis is
critical to survival and well-being, as evi-
denced by the severe clinical conse-
quences resulting from diabetes. The liver
contributes to the control of glucose me-
tabolism by uptake and storage of glu-
cose after a carbohydrate-rich meal or
by the activation of glucose production
under conditions of hypoglycemia. These
processes are orchestrated by insulin,
glucagon, and glucocorticoids. Changes
in these hormone levels have a pro-
nounced effect on the hepatic transcrip-
tional program. For example, the activa-tion of genes encoding gluconeogenic
enzymes such as phosphoenolpyruvate
carboxykinase (PEPCK) and Glucose-6-
Phosphatase (G6Pase) is controlled by
complex sets of cis-regulatory elements
and their cognate DNA-binding proteins
(reviewed in Lucas and Granner, 1992).
A new study published in Nature adds
an interesting twist to the story and pro-
poses a two-step model to elicit and
maintain activation of the gluconeogenic
transcriptional program (Liu et al., 2008).
More than 15 years ago it was discov-
ered that two classes of transcriptionalCell Metabolism 8,regulators cooperate to ensure that the
gluconeogenic program is activated only
in the appropriate cell types, that is mainly
in the hepatocytes of the liver (Schmid
et al., 1993). The promoters and en-
hancers controlling the expression of the
gluconeogenic genes contain binding
sites for both liver-enriched transcription
factors such as HNF4a and Foxa2 and
also ubiquitously expressed transcription
factors that mediate the activation of
these genes in response to the changes
in the hormonal milieu, such as the gluco-
corticoid receptor and the CREB family ofDecember 3, 2008 ª2008 Elsevier Inc. 449
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Previewstranscription factors, which responds to
changes in intracellular cAMP caused by
increased glucagon and epinephrine.
When the liver-enriched transcription fac-
tor Foxa2 was ablated specifically in he-
patocytes, binding of both CREB and
the glucocorticoid receptor to their tar-
gets in the promoters of fasting-activated
genes was impaired, resulting in attenu-
ated expression of gluconeogenic genes
(Zhang et al., 2005).
The related FoxO proteins also bind to
the cis-regulatory elements of gluconeo-
genic genes and activate their transcrip-
tion, but only in the fasted state when in-
sulin levels are low. While nuclear during
fasting, the FoxO proteins are targets for
phosphorylation by AKT in response to in-
sulin, leading to nuclear exclusion and
loss of DNA binding in the fed state.
Thus, an elegant mechanism for insulin-
dependent gene inhibition exists: Insulin
binding to its receptor on the cell surface
initiates PI3 kinase and AKT activation,
followed by FoxO phosphorylation and
nuclear exclusion. This nuclear exclusion
then results in the deactivation of FoxO
targets, which in the liver include the
genes encoding gluconeogenic enzymes.
Consequently, when FoxO1 was condi-
tionally ablated in mouse hepatocytes,
stimulation of hepatic gluconeogenesis
was impaired (Matsumoto et al., 2007).
CREB has served as a paradigm for the
identification of transcriptional coactiva-
tors. More than a decade ago, CBP, or
CREB-binding protein, was identified as
a cofactor that had profound effects on
the transcriptional readout of CREB.
CBP and the related protein p300 bind
to CREB preferentially in its Ser133-
phosphorylated form (Arias et al., 1994).
CBP/p300 have intrinsic histone acetyl
transferase activity, leading to the elegant
concept that cAMP is ultimately coupled
to loosening of chromatin structure in
the vicinity of CREB-binding sites (Korzus
et al., 1998). More recently, the discovery
of a new regulatory protein termed CREB-
regulated transcriptional coactivator
(CRTC2, originally called TORC2) formed
the basis of a competing model for
cAMP-dependent gene activation. In re-
sponse to elevated cAMP, CRTC2 binds
to CREB and increases activation of tar-
get genes including PEPCK at least in
part via increasing the association of
CREB with TAFII130, a component of the
basal transcriptional machinery (Conk-450 Cell Metabolism 8, December 3, 2008 ªright et al., 2003). Interestingly, the action
of TORC appears to be independent of
CREB-Ser133 phosphorylation (Conk-
right et al., 2003). Most recently, it has
been suggested that CRTC2 alone is the
coactivator responsible for CREB-medi-
ated transcriptional activation of the he-
patic gluconeogenic program (Koo et al.,
2005). In this model CRTC2 is phosphory-
lated by SIK1 in the basal (i.e., fed) state
and excluded from the nucleus. When
cAMP levels rise, CRTC2 is dephosphory-
lated and enters the nucleus to function as
a coactivator of CREB (Bittinger et al.,
2004).
A new collaborative study led by Marc
Montminy at the Salk Institute addresses
the question of how the liver accom-
plishes and maintains gluconeogenesis
during a prolonged fast and defines a tem-
poral switch from CRTC2 to Foxo1 as
a critical step in the process (Liu et al.,
2008). When the authors analyzed a time-
course of CRTC2 expression in the liver of
fasted mice, they made the striking dis-
covery that CRTC2 levels decrease
sharply from 6 hr to 24 hr of fasting, sug-
gesting that CRTC2 cannot mediate
gene activation at the later time point. In
contrast, Foxo1 levels were maintained
throughout. When CRTC2 expression
was suppressed with RNAi in mice,
mRNA levels of G6Pase were reduced in
the short-term fast (6 hr), but not after an
18 hr fast. The converse was true for de-
pletion of FoxO1 protein. In this case, no
effect was seen at 6 hr, but at 18 hr of fast-
ing G6Pase expression was FoxO1 de-
pendent. The effects on blood glucose
levels were not as clear-cut. While deple-
tion of FoxO1 reduced blood glucose
levels after 18 hr only, as expected, the
hypoglycemia induced by CRTC2 deple-
tion was permanent. It is not clear why
RNAi-mediated depletion of CRTC2 after
an 18 hr fast should have any effect be-
cause at this time point CRTC2 is de-
graded in control fasted mice as well.
The authors then address themolecular
mechanism that underlies the switch in
control of the gluconeogenic program.
They uncover a complex series of acetyla-
tion and deacetylation events that affect
stability and activity of both CRTC2 and
FoxO1. CRTC2 is acetylated during the
acute fast by CBP and p300, the closely
related histone acetyl transferases that
are recruited by CREB and many other
Figure 1. A Two-Step Model for the Activation of Gluconeogenic Genes during Fasting
In the fed state, both CRTC2 (also known as TORC2) and FoxO1 are localized in the cytoplasm as phos-
phoproteins. In the initial phase of fasting (up to 6 hr), CRTC2 is dephosphorylated by SIK1 and enters the
nucleus where it binds to CREB and related proteins. In the same complex, CBP/p300 acetylate CRCT2
and protect it from ubiquitin-mediated degradation. At the same time, FoxO1 is inhibited by CBP/p300
acetylation. During a prolonged fast, SIRT1 deacetylates both CRTC2 and FoxO1, with opposing out-
comes. Deacetylated CRTC2 is degraded by the proteosome, while deacetylated FoxO1 becomes
a more potent transcriptional activator. Modified from Liu et al., 2008.2008 Elsevier Inc.
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Previewstranscription factors to the promoters of
active genes. But, during a prolonged
fast, CRTC2 is deacetylated by the NAD-
dependent enzyme SIRT1, which allows
for ubiquitination of CRTC2 and degrada-
tion in the proteosome. The authors pro-
vide genetic evidence for this model by
demonstrating that in SIRT1-deficient he-
patocytes, CRTC2 cannot be degraded
even after prolonged exposure to gluca-
gon, which mimics part of the fasting
response. The authors suggest that at
later stages of the fast, deacetylation of
FoxO1 by SIRT1 leads to activation of
FoxO1, thereby maintaining glucose ho-
meostasis. This dual regulatory mecha-
nism is schematized in Figure 1.
A few questions remain for future study.
First, p300 and CBP acetylate many
proteins and, predominantly, histones of
genes primed for expression. Thus, it is
not clear how much of the effects seen
by Liu and colleagues when using p300/
CBP inhibitors in mice is due to CRTC2,
and howmuch to the other p300/CBP tar-
gets. Second, the effects of CRTC2 RNAi
suppression on the expression of PEPCKA Cholesterol Tog
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Cholesterol levels in mammalian ce
factor SREBP plays a key role. Work
of endoplasmic reticulum cholester
surprising precision.
Mammalian cell cholesterol is under con-
stant, mulitfaceted control. A key part of
this control ismediated by feedback regu-
lation of SREBP, responsible for the tran-
scription of genes encoding sterol syn-
thetic enzymes, LDL receptor, and other
lipid-related proteins. The overarching
concept is simple: when cellular choles-
terol is low, SREBP is activated, leading
to more sterol synthesis and uptake.
When cholesterol is high, SREBP be-were relatively mild, and actually larger at
18 hr than at 6 hr. Some of these issues
will surely be addressed by gene ablation
models for CRTC2 in the future. Third,
while Liu and colleagues propose that
SIRT1-mediated deacetylation of FoxO1
leads to its activation, prior work had
suggested that SIRT1 represses FoxO1
transcription factors (Motta et al., 2004).
This discrepancy was not addressed by
Liu and colleagues but will need to be
resolved in the future. What is clear, how-
ever, is that nature has devised multiple
redundant systems to ensure that the
body’s energy balance is maintained
even in periods of fasting, and that the
liver’s central role in this is controlled
by a complex system of transcriptional
regulators.
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Our detailed knowledge of SREBP reg-
ulation comes from a remarkable and on-
going odyssey of inquiry by the Brown
and Goldstein laboratory leading to an as-
tonishing collection of basic and medical
insights (Goldstein et al., 2006). SREBP
is an ER membrane protein with an at-
tached cytosolic N-terminal bZIP-HLH
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